

Publications auxquelles l'ARETASC à participé en 2012

Higher risk of locoregional recurrences for women treated with mastectomy compared with breast conserving therapy in postmenopausal women with early breast cancer treated on the TEAM trial. M van Hezewjk; ETM hille, H Outter : EBCC en Vienne 2012.

Chimiothérapie de rattrapage par gemcitabine et docetaxel dans les sarcomes. Etude rétrospective monocentrique de 14 observations. D.Hauteville, C.Rizzo, L Thomas Marques. Oncologie 2012: 14; 57-64.

Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. Asco Juin 2012 abstract 7574.

EORTC 55041 / TARCEVA / OV07: A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. A GCIIG Intergroup trial led by EORTC GCG in collaboration with AGO (Austria), ANZGOG (Australia and New Zealand), GINECO (France), MRC (UK), MANGO (Italy). Asco Juin 2012.

Bevacizumab (BEV) associé à une chimiothérapie(CT) en continu au-delà d'une première Progression chez les patients atteints de cancer colorectal métastatique(CCRm) préalablement traités par bevacizumab + CT : résultats d'une étude de phase III randomisée en intergroupe. Dirk Arnold, Thierry Andre, Jaafar Bennouna, Etude TML: abstract oral Asco Juin 2012.

Effect du Dénosumab sur la survie sans métastases osseuse chez des patients atteints de cancer de la prostate résistant à la castration (CPRC) en fonction de la cinétique du PSA communication orale Asco Juin 2012 .

Bevacizumab + chemotherapy beyond first progression in metastatic colorectal cancer patients previously treated with bevacizumab-based therapy: TML study subgroup findings WCGIC abstract Barcelone 2012.

Randomised phase III study of bevacizumab +chemotherapy beyond progression in bevacizumab-treated patients with metastatic colorectal cancer: TML study KRAS subgroup findings WCGI abstract Barcelone 2012.

Specific adverse events predict survival benefit in patients treated with tamoxifen aromatase Inhibitors – an international TEAM trial analysis Esso 20 September 2012 Spain.

Second-line erlotinib therapy in elderly patients with advanced non-small cell lung cancer: IFCT 0501 randomised phase 3 trial. Esmo Vienna October 2012, abstract 1276.

Phase trial results comparing 6 to 12 months of Trastuzumab in adjuvant early breast cancer. Esmo Vienna October 2012.

Characteristics of patients with Her-positive metastatic (mBC) or locally advanced breast cancer (aBC) treated with trastuzumab (T) as 1st line therapy and progression-free for at least 3 years: interim analysis of the LORHA study. Esmo Vienna, October 2012, abstract 346P.

Cancer du Sein: quel type de surveillance pour optimiser le suivi? : Eric Sebban, Jean Michel Vannetzel : lettre du gynécologue N°376 Novembre 2012

Primary results of BEATRICE a randomized phase III trial evaluating adjuvant bevacizumab containing therapy in triple-negative breast cancer: D. Cameron, J.Brown; R.Dent. SABCS (San Antonio), December 4- 2012.

Plasma VEGF-A and VEGFR-2 biomarker results from BEATRICE phase III trial of bevacizumab in triple negative early breast cancer: poster 3-06-34; SABCS (San Antonio) December 4-7, 2012.